BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 29696443)

  • 1. Relationship between functional imaging and immunohistochemical markers and prediction of breast cancer subtype: a PET/MRI study.
    Incoronato M; Grimaldi AM; Cavaliere C; Inglese M; Mirabelli P; Monti S; Ferbo U; Nicolai E; Soricelli A; Catalano OA; Aiello M; Salvatore M
    Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1680-1693. PubMed ID: 29696443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective Correlation of Prognostic Immunohistochemical Markers With SUV and ADC Derived From Dedicated Hybrid Breast 18F-FDG PET/MRI in Women With Newly Diagnosed Breast Cancer.
    Morawitz J; Kirchner J; Martin O; Bruckmann NM; Dietzel F; Li Y; Rischpler C; Herrmann K; Umutlu L; Bittner AK; Mohrmann S; Ingenwerth M; Häberle L; Esposito I; Antoch G; Buchbender C; Sawicki LM
    Clin Nucl Med; 2021 Mar; 46(3):201-205. PubMed ID: 33351505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
    Groheux D; Hatt M; Hindié E; Giacchetti S; de Cremoux P; Lehmann-Che J; Martineau A; Marty M; Cuvier C; Cheze-Le Rest C; de Roquancourt A; Visvikis D; Espié M
    Cancer; 2013 Jun; 119(11):1960-8. PubMed ID: 23504954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Journal Club: Diagnostic value of (18)F-FDG PET/CT and MRI in predicting the clinicopathologic subtypes of invasive breast cancer.
    Miyake KK; Nakamoto Y; Kanao S; Tanaka S; Sugie T; Mikami Y; Toi M; Togashi K
    AJR Am J Roentgenol; 2014 Aug; 203(2):272-9. PubMed ID: 25055259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of the SUVmax of FDG-PET and ADC values of diffusion-weighted MR imaging with pathologic prognostic factors in breast carcinoma.
    Kitajima K; Yamano T; Fukushima K; Miyoshi Y; Hirota S; Kawanaka Y; Miya M; Doi H; Yamakado K; Hirota S
    Eur J Radiol; 2016 May; 85(5):943-9. PubMed ID: 27130054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
    Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
    J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor metabolism and perfusion ratio assessed by 18F-FDG PET/CT and DCE-MRI in breast cancer patients: Correlation with tumor subtype and histologic prognostic factors.
    An YS; Kang DK; Jung YS; Han S; Kim TH
    Eur J Radiol; 2015 Jul; 84(7):1365-70. PubMed ID: 25886700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of tumor differentiation using sequential PET/CT and MRI in patients with breast cancer.
    Choi JH; Lim I; Noh WC; Kim HA; Seong MK; Jang S; Seol H; Moon H; Byun BH; Kim BI; Choi CW; Lim SM
    Ann Nucl Med; 2018 Jul; 32(6):389-397. PubMed ID: 29797002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reliability of
    Jena A; Taneja S; Singh A; Negi P; Sarin R; Das PK; Singhal M
    AJR Am J Roentgenol; 2017 Sep; 209(3):662-670. PubMed ID: 28678576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between standardized uptake value and apparent diffusion coefficient of neoplastic lesions evaluated with whole-body simultaneous hybrid PET/MRI.
    Rakheja R; Chandarana H; DeMello L; Jackson K; Geppert C; Faul D; Glielmi C; Friedman KP
    AJR Am J Roentgenol; 2013 Nov; 201(5):1115-9. PubMed ID: 24147485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?
    Groheux D; Majdoub M; Tixier F; Le Rest CC; Martineau A; Merlet P; Espié M; de Roquancourt A; Hindié E; Hatt M; Visvikis D
    Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1682-1691. PubMed ID: 26140849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between functional imaging markers derived from diffusion-weighted MRI and 18F-FDG PET/CT in esophageal cancer.
    Goense L; Heethuis SE; van Rossum PSN; Voncken FEM; Lagendijk JJW; Lam MGEH; Terhaard CH; van Hillegersberg R; Ruurda JP; Mook S; van Lier ALHMW; Lin SH; Meijer GJ
    Nucl Med Commun; 2018 Jan; 39(1):60-67. PubMed ID: 29023336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined
    Wu J; Zhang X; Jia Z; Zhou X; Qi R; Ji H; Sun J; Sun C; Teng Z; Lu G; Chen X
    Mol Pharm; 2022 Sep; 19(9):3405-3411. PubMed ID: 35972444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffusion-weighted imaging and (18) F-fluorodeoxyglucose positron emission tomography/computed tomography in breast cancer: Correlation of the apparent diffusion coefficient and maximum standardized uptake values with prognostic factors.
    Karan B; Pourbagher A; Torun N
    J Magn Reson Imaging; 2016 Jun; 43(6):1434-44. PubMed ID: 26663655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of FDG-PET and DWI in breast cancer.
    Kitajima K; Miyoshi Y; Yamano T; Odawara S; Higuchi T; Yamakado K
    Ann Nucl Med; 2018 Jan; 32(1):44-53. PubMed ID: 29134565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Correlations Between MRI Perfusion, Diffusion Parameters, and 18F-FDG PET Metabolic Parameters in Primary Head-and-Neck Cancer: A Cross-Sectional Analysis in Single Institute.
    Han M; Kim SY; Lee SJ; Choi JW
    Medicine (Baltimore); 2015 Nov; 94(47):e2141. PubMed ID: 26632740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new method for apparent diffusion coefficient measurement using sequential (18)F-FDG PET and MRI: correlation with histological grade of invasive ductal carcinoma of the breast.
    Byun BH; Noh WC; Lim I; Lee SS; Cho AR; Park JA; Kim KM; Kim HA; Kim EK; Kim BI; Choi CW; Lim SM
    Ann Nucl Med; 2013 Oct; 27(8):720-8. PubMed ID: 23700260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.
    Groheux D; Majdoub M; Sanna A; de Cremoux P; Hindié E; Giacchetti S; Martineau A; de Roquancourt A; Merlet P; Visvikis D; Resche-Rigon M; Hatt M; Espié M
    Radiology; 2015 Nov; 277(2):358-71. PubMed ID: 25915099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between
    Du S; Sun H; Gao S; Xin J; Lu Z; Chen Z; Pan S; Guo Q
    Clin Radiol; 2019 Mar; 74(3):178-186. PubMed ID: 30545566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between ¹⁸F-FDG uptake and molecular subtype of breast cancer.
    Kitajima K; Fukushima K; Miyoshi Y; Nishimukai A; Hirota S; Igarashi Y; Katsuura T; Maruyama K; Hirota S
    Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1371-7. PubMed ID: 25947575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.